Ligand Pharmaceuticals Inc. (LGND) Stock Quote

Detailed Quote for Ligand Pharmaceuticals Inc. (LGND)

close 52 Week Information

52 Week High

September 8, 2011

Close: 16.24

52 Week Low

February 15, 2011

Close: 9.00

Today

Last Price
14.70

Change $
0.23

Change %
1.59%

Tick
N/A

Bid
N/A

Bid Size
0

Ask
N/A

Ask Size
0

Open
14.65

High
15.43

Low
14.195

Prev Close
14.47

Last Trade
2/10/12

Volume
360.54 k

52 Wk Hi
16.24

52 Wk Low
9.00

Market Cap
289.2 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
19,673,693

EPS (TTM)
0.52

PE Ratio
28.30

close Exchange Information Listed On NASDAQ (NSD) Exchange
NSD

News and Media for Ligand Pharmaceuticals Inc. (LGND)

Sector News | Topic News

News for LGND

Thu, Feb 09, 2012

12:45 PM

Ligand to Present at the BIO CEO and Investor Conference on February 13 - Business Wire

Tue, Feb 07, 2012

4:05 PM

Ligand Reports Fourth Quarter and Full Year 2011 Financial Results - Business Wire

8:00 AM

Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development - Business Wire

Wed, Feb 01, 2012

9:45 PM

Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings - Business Wire

12:30 PM

Ligand to Report Fourth Quarter Results on February 7 - Business Wire

Wed, Jan 04, 2012

5:30 PM

Ligand to Present at the Biotech Showcase Conference on January 10th - Business Wire

Wed, Dec 21, 2011

8:00 AM

Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly - Business Wire

Mon, Dec 12, 2011

4:30 PM

Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology - Business Wire

Wed, Dec 07, 2011

5:35 PM

Ligand to Present at the Oppenheimer Healthcare Conference on December 14 - Business Wire

Tue, Sep 27, 2011

9:11 AM

Factors Moving Markets, Worldwide View - Equity Research on Ligand Pharmaceuticals Inc. and Eli Lilly & Co. - Marketwire

Tue, Dec 01, 2009

7:05 AM

New recombinant XYNTHA(TM) now available for patients with hemophilia A - Canada Newswire

7:03 AM

Le nouveau produit recombinant XYNTHA(MC) est maintenant offert aux patients atteints d'hémophilie A - Canada Newswire

Tue, Sep 22, 2009

12:26 PM

New H1N1 Treatment Could See Fast Approval From FDA - Accesswire

Mon, Sep 21, 2009

5:17 AM

Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases - Canada Newswire

Fri, Sep 18, 2009

3:06 PM

CEO says CEL-SCI could suddenly become a very important company - Accesswire

Tue, Jun 16, 2009

10:20 AM

ANAVEX appoints Dr. Herve de Kergrohen as CEO to lead company through clinical trials and future growth - Accesswire

More News for LGND >>

Tags for Ligand Pharmaceuticals Inc.

Research stocks or mutual funds related to Ligand Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to LGND. The keywords below have been associated to LGND by either user submission or electronic means.

biotechnology company aventis pharmaceuticals stock trading identity theft alert pharmaceuticals research direct marketing fare alerts marketing communications pharmaceutical market stock market shares pharmaceuticals companies generic pharmaceutical pharmaceuticals logistics pharmaceutical investment ligand pharmaceutical niche pharmaceutical 1st alert email stock alert weather alerts diabetes alert business strategies database marketing pharmaceutical research and development fx alert stock toolbar stock alert biotech and pharmaceutical dupont pharmaceuticals pharma marketing gsk traffic alerts stock quote osteoporosis treatment school alert pharmaceutical software pharma manufacturing pharmaceutical clinical research severe weather alerts stock alerts stock price list pharmaceuticals jobs pharma license rfp pharmaceuticals research consultants pfizer pharmaceutical company novartis pharmaceuticals stock market alerts kv pharmaceutical company mobile phone alert warrick pharmaceutical